ArticleSmall methods2026
Immune-Evasive Biomimetic Gold-Carbon Nanoplatform for Dual-Modal Theranostics of Hepatocellular Carcinoma.
Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) remains refractory to systemic therapy due to poor tumor selectivity, rapid drug clearance, and acquired resistance to sorafenib (SF). Here, we report a membrane-engineered biomimetic gold-carbon theranostic nanoplatform (ARG-SF@M) that integrates immune evasion, homologous targeting, dual-modal imaging, and synergistic chemo-photothermal therapy (chemo-PTT) within a single nanosystem. The platform is constructed by co-assembling gold nanorods (AuNRs) and a fluorescent carbon nanomaterial (GTTN) for efficient SF loading, followed by cloaking with HCC cell membranes to confer prolonged circulation and tumor-homotypic recognition. AuNRs enable efficient near-infrared photothermal conversion and thermal imaging (TI), while GTTN provides stable fluorescence imaging (FI) for real-time biodistribution monitoring. The membrane camouflage markedly enhances tumor accumulation and reduces off-target distribution, thereby improving SF delivery efficiency. In vivo studies demonstrate that ARG-SF@M achieves a tumor inhibition rate of 81.92%, significantly higher than that of free SF (42.43%) and non-biomimetic ARG-SF (66.05%). Under NIR irradiation, tumor suppression further increases to 90.77%, substantially outperforming AuNRs + L (55.35%), confirming strong chemo-PTT synergy. Mechanistically, photothermal activation induces intratumoral hyperthermia, mitochondrial dysfunction, excessive reactive oxygen species generation, HSP70 upregulation, and activation of the mitochondrial apoptotic pathway. Collectively, this work presents a rational biomimetic membrane-engineering strategy for imaging-guided precision HCC theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.